• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Valens Shareholders Vote In Favour Of Arrangement With SNDL

    11/29/22 5:03:14 PM ET
    $SNDL
    $VLNS
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $SNDL alert in real time by email

    The Valens Company Inc. (TSX: VLNS) (NASDAQ: VLNS) (the "Company" or "Valens") is pleased to announce that its shareholders have voted in favour of the resolution (the "Resolution") approving the plan of arrangement pursuant to which SNDL Inc. ("SNDL") will acquire all of the issued and outstanding common shares of Valens on the basis of 0.3334 of a SNDL common share for each outstanding Valens common share (the "Arrangement"), on and subject to the terms of the arrangement agreement dated August 22, 2022 to which Valens and SNDL are parties (the "Agreement"). Over 96% of votes cast at the Company's special meeting of shareholders held on November 29, 2022 were in favour of the Resolution.

    The Valens Company (CNW Group/The Valens Company Inc.)

    "With this announcement, we are one step closer to combining two best-in-class cannabis companies that have extremely complementary assets to create a true market leader. This pro forma company will create Canada's first large vertically integrated cannabis company that unites SNDL's exceptional balance sheet and largest cannabis retail network in Canada with Valens' low-cost manufacturing platform. We look forward to taking Valens' brands to new heights and unlocking 2.0 products for the SNDL platform," said Tyler Robson, Chief Executive Officer of The Valens Company. "We believe the pro forma company provides investors with attractive exposure not only to the highest revenue generating cannabis company in Canada trading well under its tangible book value but also a dominant platform that can become a global leader in cannabis."

    Arrangement Resolution Voting Results

    CATEGORY OF VOTING

    VOTES FOR

    % VOTES FOR

    VOTES

    AGAINST

    % VOTES

    AGAINST

    All voting shareholders

    33,929,706

    96.96 %

    1,063,247

    3.04 %

    All voting shareholders except those required to be excluded for the purposes of "minority approval" under Multilateral Instrument 61-101

    31,909,073

    96.78 %

    1,063,247

    3.22 %



    A report on voting results will be filed under the Company's profile on SEDAR at www.sedar.com.

    The Arrangement is expected to close in January 2023, subject to the satisfaction and/or waiver of the closing conditions set forth in the Agreement, including, among other things, final court approval from the Ontario Superior Court of Justice (Commercial List). 

    At Valens, it's Personal.

    Get the next $SNDL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SNDL
    $VLNS

    CompanyDatePrice TargetRatingAnalyst
    SNDL Inc.
    $SNDL
    9/3/2025$5.00Buy
    Alliance Global Partners
    SNDL Inc.
    $SNDL
    7/17/2024Speculative Buy
    Canaccord Genuity
    SNDL Inc.
    $SNDL
    8/16/2022$5.00Hold → Speculative Buy
    Canaccord Genuity
    SNDL Inc.
    $SNDL
    5/3/2022$0.60 → $0.70Underperform → Market Perform
    BMO Capital Markets
    The Valens Company Inc.
    $VLNS
    3/3/2022Market Perform → Underperform
    Raymond James
    More analyst ratings

    $SNDL
    $VLNS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SNDL Reports Fourth Quarter and Full Year 2025 Financial and Operational Results

    EDMONTON, Alberta, March 12, 2026 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL" or the "Company") reported its financial and operational results for the full year and fourth quarter ended December 31, 2025. All financial information in this press release is reported in millions of Canadian dollars unless otherwise indicated. SNDL has also posted a supplemental investor presentation on its website, found at https://sndl.com. The Company will hold a conference call and webcast presentation at 10:00 a.m. EDT (8:00 a.m. MDT) on Thursday, March 12, 2026. The conference call details can be found below. MANAGEMENT HIGHLIGHTS Net revenue for the fourth quarter of 2025 was $252.

    3/12/26 6:55:00 AM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL to Report Fourth Quarter 2025 and Full Year 2025 Financial Results on March 12, 2026

    EDMONTON, Alberta, Feb. 19, 2026 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL") announced today that it will release its fourth quarter and full year 2025 financial results for the period ended December 31, 2025, before markets open on Thursday, March 12, 2026. Following the release of its fourth quarter results, SNDL will host a conference call and webcast at 10:00 a.m. EDT (8:00 a.m. MDT) on March 12, 2026. WEBCAST ACCESS To access the live webcast of the call, please visit the following link: https://edge.media-server.com/mmc/p/aps8jm4e ABOUT SNDL INC.  SNDL Inc. (NASDAQ:SNDL, CSE:SNDL), through its wholly owned subsidiaries, is one of the largest vertically integr

    2/19/26 4:30:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL & 1CM Complete Purchase and Sale of 5 Retail Stores in Alberta and Saskatchewan

    EDMONTON, Alberta and TORONTO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL") and 1CM Inc. (CSE:EPIC) (OTCQB:MILFF) (FSE: IQ70) ("1CM") are pleased to announce that SNDL has completed the acquisition of 5 cannabis retail stores located in Alberta and Saskatchewan from 1CM. The transaction represents the completion of the first closing pursuant to the amended and restated arrangement agreement dated December 15, 2025 (the "A&R Arrangement Agreement"). As previously announced, it is anticipated that the second (and final) closing will occur sometime in the first half of 2026, in respect of 27 additional cannabis retail stores located in Ontario, subject to obta

    1/7/26 4:30:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    $SNDL
    $VLNS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on SNDL Inc. with a new price target

    Alliance Global Partners initiated coverage of SNDL Inc. with a rating of Buy and set a new price target of $5.00

    9/3/25 7:54:28 AM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    Canaccord Genuity resumed coverage on SNDL Inc.

    Canaccord Genuity resumed coverage of SNDL Inc. with a rating of Speculative Buy

    7/17/24 12:19:57 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    Sundial Growers upgraded by Canaccord Genuity with a new price target

    Canaccord Genuity upgraded Sundial Growers from Hold to Speculative Buy and set a new price target of $5.00

    8/16/22 7:59:34 AM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    $SNDL
    $VLNS
    SEC Filings

    View All

    SEC Form 6-K filed by SNDL Inc.

    6-K - SNDL Inc. (0001766600) (Filer)

    3/12/26 6:55:05 AM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by SNDL Inc.

    6-K - SNDL Inc. (0001766600) (Filer)

    2/19/26 4:40:03 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by SNDL Inc.

    6-K - SNDL Inc. (0001766600) (Filer)

    1/7/26 4:32:18 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    $SNDL
    $VLNS
    Leadership Updates

    Live Leadership Updates

    View All

    $SNDL
    $VLNS
    Financials

    Live finance-specific insights

    View All

    SNDL Announces 2025 Annual and Special Meeting Results

    EDMONTON, AB, July 31, 2025 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) (CSE:SNDL) ("SNDL" or the "Company") is pleased to announce the resolutions put to holders of common shares (the "Shareholders") at the Annual and Special Meeting of Shareholders (the "Meeting") were passed. At the Meeting, Shareholders approved: (i) fixing the number of directors of the board at seven (7); (ii) electing each of Gregory Mills, J. Carlo Cannell, Lori Ell, Zachary George, Frank Krasovec, Bryan Pinney, and Gregory Turnbull as directors of the Company for the ensuing year; (iii) re-appointing CBIZ

    7/31/25 4:30:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL Appoints New Chief Information Officer and New President, Liquor Division

    CALGARY, AB, Nov. 21, 2024 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) ("SNDL" or the "Company") is pleased to announce the appointments of Phil McBride as Chief Information Officer and Navroop Sandhawalia as President, Liquor Division. "SNDL's success is driven by our commitment to talent density and our leaders are the foundation of our performance culture," said Zach George, Chief Executive Officer of SNDL.  "Phil's extensive expertise in technology and digital innovation, paired with Nav's financial acumen and best-in-class retail experience will further strengthen our executio

    11/21/24 6:02:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL Announces 2024 Annual General Meeting Results

    CALGARY, AB, July 30, 2024 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) ("SNDL" or the "Company") is pleased to announce the resolutions put to holders of common shares (the "Shareholders") at the Annual General Meeting (the "Meeting") were passed. At the Meeting, Shareholders approved: (i) fixing the number of directors of the board at six (6); (ii) electing each of Gregory Mills, Zachary George, Lori Ell, Frank Krasovec, Bryan Pinney and Gregory Turnbull as directors of the Company for the ensuing year; and (iii) re-appointing Marcum LLP as the auditors of the Company for the ensu

    7/30/24 5:45:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL Reports Fourth Quarter and Full Year 2025 Financial and Operational Results

    EDMONTON, Alberta, March 12, 2026 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL" or the "Company") reported its financial and operational results for the full year and fourth quarter ended December 31, 2025. All financial information in this press release is reported in millions of Canadian dollars unless otherwise indicated. SNDL has also posted a supplemental investor presentation on its website, found at https://sndl.com. The Company will hold a conference call and webcast presentation at 10:00 a.m. EDT (8:00 a.m. MDT) on Thursday, March 12, 2026. The conference call details can be found below. MANAGEMENT HIGHLIGHTS Net revenue for the fourth quarter of 2025 was $252.

    3/12/26 6:55:00 AM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL to Report Fourth Quarter 2025 and Full Year 2025 Financial Results on March 12, 2026

    EDMONTON, Alberta, Feb. 19, 2026 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL") announced today that it will release its fourth quarter and full year 2025 financial results for the period ended December 31, 2025, before markets open on Thursday, March 12, 2026. Following the release of its fourth quarter results, SNDL will host a conference call and webcast at 10:00 a.m. EDT (8:00 a.m. MDT) on March 12, 2026. WEBCAST ACCESS To access the live webcast of the call, please visit the following link: https://edge.media-server.com/mmc/p/aps8jm4e ABOUT SNDL INC.  SNDL Inc. (NASDAQ:SNDL, CSE:SNDL), through its wholly owned subsidiaries, is one of the largest vertically integr

    2/19/26 4:30:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL & 1CM Complete Purchase and Sale of 5 Retail Stores in Alberta and Saskatchewan

    EDMONTON, Alberta and TORONTO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL") and 1CM Inc. (CSE:EPIC) (OTCQB:MILFF) (FSE: IQ70) ("1CM") are pleased to announce that SNDL has completed the acquisition of 5 cannabis retail stores located in Alberta and Saskatchewan from 1CM. The transaction represents the completion of the first closing pursuant to the amended and restated arrangement agreement dated December 15, 2025 (the "A&R Arrangement Agreement"). As previously announced, it is anticipated that the second (and final) closing will occur sometime in the first half of 2026, in respect of 27 additional cannabis retail stores located in Ontario, subject to obta

    1/7/26 4:30:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    $SNDL
    $VLNS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by SNDL Inc. (Amendment)

    SC 13G/A - SNDL Inc. (0001766600) (Filed by)

    1/31/24 4:48:48 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by SNDL Inc. (Amendment)

    SC 13G/A - SNDL Inc. (0001766600) (Subject)

    2/14/23 5:28:02 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by SNDL Inc. (Amendment)

    SC 13G/A - SNDL Inc. (0001766600) (Filed by)

    2/13/23 4:06:09 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care